Related Experiment Videos
Immunoregulation with methisoprinol in Sjögren's syndrome
Allergologia Et Immunopathologia
|January 1, 1986
Summary
Methisoprinol showed no clinical improvement for Sjögren
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Sjögren's syndrome (SS) is an autoimmune disease affecting exocrine glands.
- Therapeutic options for SS are limited, necessitating research into novel treatments.
Purpose of the Study:
- To evaluate the clinical efficacy and immunoregulating effects of methisoprinol in primary and secondary Sjögren's syndrome.
- To identify patient subgroups that may benefit from methisoprinol treatment.
Main Methods:
- A small cohort study involving 5 patients with Sjögren's syndrome (4 primary, 1 secondary).
- Treatment with methisoprinol for 12 weeks.
- Assessment of clinical parameters (glandular histology, Schirmer's test, sialography) and immunological markers (T-lymphocyte subsets, IgM).
Main Results:
- No significant improvements in glandular histology, Schirmer's test, or sialography after 12 weeks.
- Methisoprinol induced immunological changes: increased total T-lymphocytes (OKT3) and T-helper cells (OKT4), and decreased IgM.
- The best immunological response was observed in patients with early-stage disease, negative histology, and parotid gland functional alterations.
Conclusions:
- Methisoprinol did not demonstrate significant clinical efficacy in established Sjögren's syndrome.
- Methisoprinol modulated immune responses, suggesting potential as a coadjuvant therapy.
- Early-stage primary Sjögren's syndrome with functional alterations, but without glandular atrophy, may represent a suitable indication for methisoprinol as an adjunct treatment.